U.S. Capital Markets Stock News

NasdaqGS:APP
NasdaqGS:APPSoftware

Dow Futures Inch Higher as Rate Cut Bets Rise

The Morning Bull - US Market Morning Update Wednesday, Oct, 8 2025 US stock futures are inching higher this morning as investors try to look past a stalled federal budget deal and signs that consumer sentiment is slipping. The ongoing government shutdown along with a notable slowdown in consumer credit growth are fueling uncertainty, making investors laser-focused on whether the Federal Reserve will follow through with expected rate cuts to help shore up confidence across the broader...
NasdaqGM:AISP
NasdaqGM:AISPSoftware

Why Airship AI Holdings (AISP) Is Up 27.5% After Securing $11 Million Federal AI Contract Wins

In early October 2025, Airship AI Holdings announced it was awarded 16 contracts totaling US$11.0 million from the US Department of Justice and Department of Homeland Security to provide AI-driven surveillance solutions for public safety and investigations. The selection of Airship AI's Outpost AI platform, following successful pilot deployments that replaced prior systems, highlights increasing federal confidence in the company's proprietary threat detection technology. We'll examine how...
NasdaqGS:BMEA
NasdaqGS:BMEABiotechs

Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next

Biomea Fusion, Inc. recently announced positive 52-week results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes, reporting statistically significant and clinically meaningful reductions in HbA1c, especially for patients with severe insulin-deficient diabetes and those not reaching glycemic targets on GLP-1 therapy. The favorable safety profile and planned next steps, including additional trials and ongoing studies, highlight the company’s continued progress in...
NYSE:CABO
NYSE:CABOMedia

How Investors Are Reacting To Cable One (CABO) Sluggish Subscriber Growth and Projected Sales Decline

Recently, news highlighted that Cable One is facing sluggish subscriber trends and a projected sales decline, pointing to deteriorating business performance in the most recent quarter. An important insight is that continued operational and financial headwinds, especially from weakening subscriber growth, have amplified investor concerns regarding the company's outlook and risk profile. We'll examine how these slowing subscriber additions and anticipated revenue declines may reshape Cable...
NasdaqGS:GDRX
NasdaqGS:GDRXHealthcare Services

Is GoodRx Poised for a Turnaround After Recent Share Price Rebound in 2025?

If you have been watching GoodRx Holdings lately, you are probably weighing whether its current price reflects a hidden bargain or just more risk. At $4.39, the stock has certainly traveled a bumpy road. Despite a nice pop of nearly 4% over the last week, and almost 10% across the past month, the longer-term chart remains tough to ignore. Down roughly 37% over the last year and an eye-catching 92% since its five-year high, GoodRx has given investors moments of excitement mixed with plenty of...
NYSE:HR
NYSE:HRHealth Care REITs

How Attractive Is Healthcare Realty Trust After Its Recent Quarterly Results in 2025?

If you're considering what to do with your Healthcare Realty Trust shares, or perhaps thinking about making a move, you're not alone. The stock has been making waves, sometimes subtle, sometimes more noticeable. Over just the past week, there was a minimal dip of -0.1%, and the past month has seen a slightly larger decline of -1.8%. Yet, zooming out, things look far sunnier: Healthcare Realty Trust is up 7.7% so far this year and a solid 9.5% over the last twelve months. Of course, anyone who...
NYSE:SPNT
NYSE:SPNTInsurance

Is SiriusPoint Still Attractive After Three-Year 259% Rally and Industry Tailwinds in 2025?

If you’ve been tracking SiriusPoint’s stock, you know this isn’t one of those sleepwalking tickers. Whether you’re eyeing that impressive 259.4% gain over the last three years or sizing up this year’s 15.8% return, SiriusPoint has certainly kept things interesting for shareholders. Even with a slight dip over the last month, it’s clear that investors are reassessing the company’s growth prospects and its risk, potentially setting up for the next big move. Much of the recent momentum seems...
NasdaqGM:SKYE
NasdaqGM:SKYEBiotechs

A Look at Skye Bioscience (SKYE) Valuation After Its Phase 2a Nimacimab Topline Update

Skye Bioscience (SKYE) has scheduled a special call to present topline data from its Phase 2a clinical trial of Nimacimab, focusing on both monotherapy and combination treatment. Updates like these frequently shape investor sentiment around development-stage biotech stocks. See our latest analysis for Skye Bioscience. Skye Bioscience’s latest topline clinical update arrives after a period of muted share price action. Its stock closed at $1.90 and has shown minimal momentum over recent months...
NYSE:SHCO
NYSE:SHCOHospitality

Is Soho House a Hidden Opportunity After 69% Share Price Surge and Improved Profit Outlook?

If you are looking for the next move on Soho House & Co stock, you have probably noticed its eye-catching trajectory. This is not a slow and steady story, but one with dramatic swings and the kind of big numbers that spark conversation. Just over the past year, Soho House & Co’s shares have surged 69.1%. If you stretch that lens out to three years, we are talking 114.5% growth, which is well beyond what most lifestyle or hospitality names can boast. Even in recent months, the stock has kept...
NasdaqGS:RUSH.A
NasdaqGS:RUSH.ATrade Distributors

Evaluating Rush Enterprises Shares After Recent 14% Slide and Truck Market Uncertainty

If you have been watching Rush Enterprises, you may be asking yourself whether now is the moment to buy, hold, or move on. The stock price has slipped by 7.3% in the past week and it is down more than 14% over the last month. Year to date, shares have shed 8.8%. On a longer horizon, however, Rush Enterprises has quietly put together an impressive run, climbing 70.8% over three years and more than doubling investors’ money over five years with a 114.6% gain. That kind of return turns heads,...